Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' SINANGIL F' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 23 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. McFarland, EJ; Borkowsky, W; Fenton, T; Wara, D; McNamara, J; Samson, P; Kang, MH; Mofenson, L; Cunningham, C; Duliege, AM; Sinangil, F; Spector, SA; Jimenez, E; Bryson, Y; Burchett, S; Frenkel, LM; Yogev, R; Gigliotti, F; Luzuriaga, K; Livingston, RA
      Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine

      JOURNAL OF INFECTIOUS DISEASES
    2. Rothstein, EP; Anderson, EL; Decker, MD; Poland, GA; Reisinger, KS; Blatter, MM; Jacobson, RM; Mink, CM; Gennevois, D; Izu, AE; Sinangil, F; Langenberg, AGM
      An acellular pertussis vaccine in healthy adults: safety and immunogenicity

      VACCINE
    3. VanCott, TC; Mascola, JR; Loomis-Price, LD; Sinangil, F; Zitomersky, N; McNeil, J; Robb, ML; Birx, DL; Barnett, S
      Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope

      JOURNAL OF VIROLOGY
    4. ZOLLAPAZNER S; LUBECK M; XU S; BURDA S; NATUK RJ; SINANGIL F; STEIMER K; GALLO RC; EICHBERG JW; MATTHEWS T; ROBERTGUROFF M
      INDUCTION OF NEUTRALIZING ANTIBODIES TO T-CELL LINE-ADAPTED AND PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES WITH A PRIME-BOOST VACCINE REGIMEN IN CHIMPANZEES

      Journal of virology
    5. ROBERTGUROFF M; KAUR H; PATTERSON LJ; LENO M; CONLEY AJ; MCKENNA PM; MARKHAM PD; RICHARDSON E; ALDRICH K; ARORA K; MURTY L; CARTER L; ZOLLAPAZNER S; SINANGIL F
      VACCINE PROTECTION AGAINST A HETEROLOGOUS, NON-SYNCYTIUM-INDUCING, PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS

      Journal of virology (Print)
    6. CLEMENTSMANN ML; WEINHOLD K; MATTHEWS TJ; GRAHAM BS; GORSE GJ; KEEFER MC; MCELRATH MJ; HSIEH RH; MESTECKY J; ZOLLAPAZNER S; MASCOLA J; SCHWARTZ D; SILICIANO R; COREY L; WRIGHT PF; BELSHE R; DOLIN R; JACKSON S; XU S; FAST P; WALKER MC; STABLEIN D; EXCLER JL; TARTAGLIA J; DULIEGE AM; SINANGIL F; PAOLETTI E
      IMMUNE-RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 INDUCEDBY CANARYPOX EXPRESSING HIV-1(MN) GP120, HIV-1(SF2) RECOMBINANT GP120, OR BOTH VACCINES IN SERONEGATIVE ADULTS

      The Journal of infectious diseases
    7. LUBECK MD; NATUK R; MYAGKIKH M; KALYAN N; ALDRICH K; SINANGIL F; ALIPANAH S; MURTHY SCS; CHANDA PK; NIGIDA SM; MARKHAM PD; ZOLLAPAZNER S; STEIMER K; WADE M; REITZ MS; ARTHUR LO; MIZUTANI S; DAVIS A; HUNG PP; GALLO RC; EICHBERG J; ROBERTGUROFF M
      LONG-TERM PROTECTION OF CHIMPANZEES AGAINST HIGH-DOSE HIV-1 CHALLENGEINDUCED BY IMMUNIZATION

      Nature medicine
    8. DEMARTINO M; PODDA A; GALLI L; SINANGIL F; MANNELLI F; ROSSI ME; VIERUCCI A
      ACELLULAR PERTUSSIS-VACCINE IN CHILDREN WITH PERINATAL HUMAN-IMMUNODEFICIENCY-VIRUS-TYPE-1 INFECTION

      Vaccine
    9. ZOLLAPAZNER S; ALVING C; BELSHE R; BERMAN P; BURDA S; CHIGURUPATI P; CLEMENTS ML; DULIEGE AM; EXCLER JL; HIOE C; KAHN J; MCELRATH MJ; SHARPE S; SINANGIL F; STEIMER K; WALKER MC; WASSEF N; XU S
      NEUTRALIZATION OF A CLADE-B PRIMARY ISOLATE BY SERA FROM HUMAN-IMMUNODEFICIENCY-VIRUS-UNINFECTED RECIPIENTS OF CANDIDATE AIDS VACCINES

      The Journal of infectious diseases
    10. PAXTON WB; COOMBS RW; MCELRATH MJ; KEEFER MC; HUGHES J; SINANGIL F; CHERNOFF D; DEMETER L; WILLIAMS B; COREY L
      LONGITUDINAL ANALYSIS OF QUANTITATIVE VIROLOGICAL MEASURES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED SUBJECTS WITH GREATER-THAN-OR-EQUAL-TO-400 CD4 LYMPHOCYTES - IMPLICATIONS FOR APPLYING MEASUREMENTS TO INDIVIDUAL PATIENTS

      The Journal of infectious diseases
    11. GRAHAM BS; KEEFER MC; MCELRATH MJ; GORSE GJ; SCHWARTZ DH; WEINHOLD K; MATTHEWS TJ; ESTERLITZ JR; SINANGIL F; FAST PE; WRIGHT PF; DOLIN R; COREY L; BELSHE RB; CLEMENTS ML; BOLOGNESI DP; STABLEIN DM; CHERNOFF D; DULIEGE AM; WALKER CM
      SAFETY AND IMMUNOGENICITY OF A CANDIDATE HIV-1 VACCINE IN HEALTHY-ADULTS - RECOMBINANT GLYCOPROTEIN (RGP)-120 - A RANDOMIZED, DOUBLE-BLIND TRIAL

      Annals of internal medicine
    12. ROBERTGUROFF M; NATUK RJ; MYAGKIKH M; ALDRICH K; ALIPANAH S; KALYAN N; MURTHY SCS; WADE MS; SINANGIL F; STEIMER K; NIGIDA SM; ARTHUR LO; MARKHAM PD; GALLO RC; EICHBERG JW; LUBECK MD
      ADENOVIRUS-HIV-1(MN) ENV RECOMBINANTS AND A SF2 GP120 BOOST PROTECT CHIMPANZEES FROM A SF2 CHALLENGE

      AIDS research and human retroviruses
    13. KAHN JO; STEIMER KS; BAENZIGER J; DULIEGE AM; FEINBERG M; ELBEIK T; CHESNEY M; MURCAR N; CHERNOFF D; SINANGIL F
      CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OBSERVATIONS RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-I INFECTION IN A VOLUNTEER IN AN HIV-1 VACCINE CLINICAL-TRIAL

      The Journal of infectious diseases
    14. STEIMER KS; SINANGIL F; KAHN J; CHERNOFF D; DULIEGE AM; BAENZIGER J
      PRIMARY ISOLATE NEUTRALIZING ACTIVITY OF HUMAN-ANTIBODIES DIRECTED TORECOMBINANT, NATIVE HIV-SF2 GP120 (RGP120(SF2))

      AIDS research and human retroviruses
    15. KAHN J; CHERNOFF D; SINANGIL F; BAENZIGER J; MURCAR N; COLEMAN R; WYNNE D; LEE D; HESTERMAN K; SAKAMOTO D; CUISON G; DEKKER C; STEIMER KS
      ONE-YEAR FOLLOW-UP OF A PHASE-1 STUDY OF HIV-1 GP120 VACCINE COMBINEDWITH MF59 AND WITH A DOSE-ESCALATION OF MTP-PE IN HIV-1 NONINFECTED ADULTS

      AIDS research and human retroviruses
    16. CHERNOFF D; LANG W; SINANGIL F; BAENZIGER J; STEINER K; DEKKER C
      COMPARATIVE SAFETY AND VACCINE IMMUNOGENICITY OF YEAST-DERIVED, DENATURED, NONGLYCOSYLATED HIV-1 SF2 GP120 (ENV-2-3) VS CHO-DERIVED, CONFORMATIONALLY INTACT GLYCOSYLATED GP120 IN HIV-1 SEROPOSITIVE SUBJECTS

      AIDS research and human retroviruses
    17. STEIMER KS; SINANGIL F; BAENZIGER J; KAHN J; DINA D
      MAPPING OF B-CELL AND T-CELL RESPONSES OF HIV-1 SERONEGATIVE INDIVIDUALS VACCINATED WITH RECOMBINANT HIV-SF2 GP120

      AIDS research and human retroviruses
    18. KAHN JO; SINANGIL F; BAENZIGER J; MURCAR N; WYNNE D; COLEMAN RL; STEIMER KS; DEKKER CL; CHERNOFF D
      CLINICAL AND IMMUNOLOGICAL RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE 1(SF2) GP120 SUBUNIT VACCINE COMBINED WITH MF59 ADJUVANT WITH OR WITHOUT MURAMYL TRIPEPTIDE DIPALMITOYL PHOSPHATIDYLETHANOLAMINE IN NON-HIV-INFECTED HUMAN VOLUNTEERS

      The Journal of infectious diseases
    19. STEIMER K; BAENZIGER J; KAHN J; VANNEST G; CHERNOFF D; DEKKER C; SINANGIL F
      PRECLINICAL IMMUNOGENICITY STUDIES IN BABOONS WITH CANDIDATE HIV-1 SUBUNIT VACCINES PREDICT THE HUMAN IMMUNE-RESPONSE

      AIDS research and human retroviruses
    20. KAHN J; CHERNOFF D; SINANGIL F; MURCAR N; WYNNE D; COLEMAN R; STEIMER K; DEKKER C
      PHASE-1 DOSE-ESCALATION MTP-PE STUDY OF AN HIV-1 GP120 VACCINE IN SERONEGATIVE ADULTS

      AIDS research and human retroviruses
    21. KAHN J; CHERNOFF D; SINANGIL F; BAENZIGER J; MURCAR N; WYNNE D; COLEMAN R; STEIMER K; DEKKER C
      PHASE-STUDY OF AN HIV-1 GP 120 VACCINE COMBINED WITH THE NOVEL ADJUVANT EMULSION, MF59 AND THE BIOLOGIC RESPONSE MODIFIER MTP-PE IN HIV SERONEGATIVE ADULTS

      Journal of cellular biochemistry
    22. SAKAMOTO D; BAENZIGER J; SINANGIL F; LEE D; TURCK C; STEIMER K
      AN IMPROVED METHOD FOR ASSESSING ANTIBODY-RESPONSES TO THE PRINCIPAL NEUTRALIZING DETERMINANT (PND) OF HIV-1 GP120

      Journal of cellular biochemistry
    23. SINANGIL F; TRIBBICK G; MASON T; KAHN J; CHERNOFF D; STEIMER K
      MAPPING OF ANTIBODY-RESPONSES OF HIV-1 SERONEGATIVE INDIVIDUALS VACCINATED WITH RECOMBINANT HIV-SF2 GP120

      Journal of cellular biochemistry


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/10/20 alle ore 22:46:55